Loading clinical trials...

A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

A Randomized, Double-blind, Placebo and Active-Controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus

NCT00839527•GlaxoSmithKline

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•type 2 diabetes
•BMI 20-45kg/m2 inclusive

Exclusion Criteria

•females who are pregnant, lactating, or less than 6 weeks post-partum
•current symptomatic heart failure (NYHA Class II-IV)

Locations (358)

GSK Investigational Site

Alabaster, Alabama, United States

GSK Investigational Site

Birmingham, Alabama, United States

GSK Investigational Site

Birmingham, Alabama, United States

GSK Investigational Site

Birmingham, Alabama, United States

GSK Investigational Site

Dothan, Alabama, United States

GSK Investigational Site

Mobile, Alabama, United States

GSK Investigational Site

Tuscaloosa, Alabama, United States

GSK Investigational Site

Chandler, Arizona, United States

GSK Investigational Site

Gilbert, Arizona, United States

GSK Investigational Site

Green Valley, Arizona, United States

Key Dates

Start Date

February 1, 2009

Primary Completion Date

January 1, 2012

Completion Date

April 1, 2013

Last Updated

January 9, 2017

Enrollment

685

ACTUAL participants

Conditions

Diabetes Mellitus, Type 2

Interventions

placebo to match albiglutide

DRUG

albiglutide

BIOLOGICAL

metformin

DRUG

glimepiride

DRUG

pioglitazone

DRUG

placebo to match pioglitazone

DRUG

Sponsors

Lead Sponsor

GlaxoSmithKline

Related Studies

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

NCT06959901

Obesity and Diabetes Mellitus, Type 2Diabetes Prevention

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

NCT06574035

Diabetes Mellitus, Type 2Depressive Symptoms+1 more

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 9, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions